藥品參考
Somapacitan
Somapacitan is a medicine in the class endocrine. It is used for growth failure.
- 藥物類別: Endocrine
- 用途: growth failure
最後更新 來源: US FDA label
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
重點資訊
- 藥物類別
- Endocrine
- ATC 代碼
- H01AC07
- 常見劑型
- 注射劑
- 已知交互作用
- 101 (中度: 62 · 輕微: 39)
- 商品名
- 2
- 國家與市場
- 2
用途
作用方式
Somapacitan-beco binds to a dimeric GH receptor on target cells, causing intracellular signal transduction. Some effects are mediated mainly by IGF-1 produced in the liver, others are direct effects of somapacitan-beco.
成人常用劑量（仿單摘要）
Adult GHD: start 1.5 mg subcutaneously once weekly (treatment-naive or switching from daily GH); increase every 2 to 4 weeks by approximately 0.5 mg to 1.5 mg based on clinical response and IGF-1; maximum 8 mg once weekly
懷孕與哺乳
- 懷孕
- Unknown No data for this long-acting growth hormone; decades of short-acting growth hormone use in pregnancy show no drug-related risk, and animals showed no birth defects. UK label: not recommended in pregnancy or without contraception. Growth hormone is usually stopped once pregnancy is confirmed.
- 哺乳
- Unknown No human data; it passes into rat milk. UK label: decide whether to stop breastfeeding or the drug. LactMed: a large, poorly absorbed molecule unlikely to reach the infant, but with no experience an alternative may be preferred with a newborn or preterm infant.
已通報的副作用
- Nasopharyngitis
- Headache
- Pyrexia
- Pain in extremity
- Injection site reaction
- Cough
禁忌症
- Acute critical illness after open-heart surgery, abdominal surgery or multiple accidental trauma, or acute respiratory failure
- Hypersensitivity to SOGROYA or any of its excipients
- Pediatric patients with closed epiphyses
哪些人需要特別留意
- Increased mortality in acute critical illness
- Severe hypersensitivity including anaphylaxis and angioedema may occur
- Neoplasm risk: monitor patients with preexisting tumors; second neoplasm risk in childhood cancer survivors
請告知藥師或醫師您是否懷孕或哺乳、是否患有腎臟或肝臟疾病、是否有過敏，以及您正在使用的所有其他藥物或保健品。
重要交互作用 (101)
- Alogliptin + Somapacitan Moderate
- Alogliptin-metformin + Somapacitan Moderate
- Alogliptin-pioglitazone + Somapacitan Moderate
- Bazedoxifene-conjugated estrogens + Somapacitan Moderate
- Canagliflozin-metformin + Somapacitan Moderate
- Chlorpropamide + Somapacitan Moderate
- Cyclosporin + Somapacitan Moderate
- Dapagliflozin-metformin + Somapacitan Moderate
- Deflazacort + Somapacitan Moderate
- Desogestrel-ethinyl estradiol + Somapacitan Moderate
Pro+ 會員專屬
解鎖完整頁面
建立帳號並開始 Pro+ 試用，即可開啟 Somapacitan 的完整藥品專論：劑量、懷孕與哺乳、副作用、警示及所有交互作用。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Paediatric dosing
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
在網頁版免費試用 Pro+ 14 天，無需信用卡。
同類別的其他藥品
常見問題
What is Somapacitan used for?
Somapacitan is a medicine in the class endocrine. It is used for Growth failure, Growth hormone deficiency.
What side effects have been reported with Somapacitan?
Nasopharyngitis, Headache, Pyrexia, Pain in extremity, Injection site reaction, Cough.
Can Somapacitan be taken in pregnancy or while breastfeeding?
Pregnancy: Unknown. No data for this long-acting growth hormone; decades of short-acting growth hormone use in pregnancy show no drug-related risk, and animals showed no birth defects. UK label: not recommended in pregnancy or without contraception. Growth hormone is usually stopped once pregnancy is confirmed. Breastfeeding: Unknown. No human data; it passes into rat milk. UK label: decide whether to stop breastfeeding or the drug. LactMed: a large, poorly absorbed molecule unlikely to reach the infant, but with no experience an alternative may be preferred with a newborn or preterm infant.
What does Somapacitan interact with?
MediHelp lists 101 known interactions for Somapacitan. Moderate: 62 · Minor: 39. The most serious include Alogliptin, Alogliptin-metformin, Alogliptin-pioglitazone.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
